Axon Therapies, Inc.

Cibiem, Inc.

Johns Hopkins University

Coridea, LLC

Zoar Jacob Engelman

Howard Levin

Mark Gelfand

Mark S Leung

Dorin Panescu

Andrew H Wu

Martin Maitre Grasse

Manuel Arzadon Javier, Jr

Pajhand Iranitalab

Thomas Ryan McGrath

Casey Andrew Miller

Anisha Bapna

Brett Daniel Schleicher

Charles Lennox

Anne Marie Ahonen

Marat Fudim

Nicholas C VanDillen

Tamara Colette Baynham

Veijo T Suorsa

Ary S Chernomorsky

Miriam H Taimisto

Yegor D Sinelnikov

Kenneth M Martin

Harikrishna Tandri

Jason Michael Miller

Michael Brick Markham

Manuel Arzadon Javier

Thomas Ryan Mcgrath

Nicholas C Vandillen

Martin M Grasse

Timothy A Koss

Xian Wei

Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.

Methods and devices for endovascular ablation of a splanchnic nerve

Systems, devices, and methods for transvascular ablation of target tissue are disclosed herein. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.

Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.

Devices, systems, and methods for treatment of heart failure by splanchnic nerve ablation

Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are method of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.

Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying stimulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.

Methods and devices for treating patients having cardiopulmonary disease such as cardiac arrhythmias, ventricular arrhythmias, pulmonary hypertension, or heart failure comprising a tracheal approach. The method includes ablating a deep cardiac plexus of a patient by advancing an treatment apparatus into a trachea of the patient, extending an ablative energy delivery element of the treatment apparatus through a wall of the trachea at a level of the trachea proximate a tracheal bifurcation, positioning the ablative energy delivery element at a target space between the trachea, an aorta and a pulmonary artery, and ablating, by the ablative energy delivery element, tissue within the target space to substantially disable the deep cardiac plexus.

Method and apparatus to treat cardiopulmonary disease

Methods and devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation.

Carotid body ablation with a transvenous ultrasound imaging and ablation catheter

Methods and cryogenic devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via carotid body ablation. Some methods include advancing a cryo-ablation catheter into a patient's vasculature and ablating tissue within a carotid septum.

Methods and devices for cryogenic carotid body ablation

Methods and percutaneous devices for assessing, and treating patients having sympathetically mediated disease, involving augmented peripheral chemoreflex and heightened sympathetic tone by reducing chemosensor input to the nervous system via percutaneous carotid body ablation.

Percutaneous methods and devices for carotid body ablation

Systems, devices, and methods for treating a patient having a sympathetically mediated disease associated at least in part with augmented peripheral chemoreflex or heightened sympathetic activation. The treatments include ablating one or more peripheral chemoreceptors or associated afferent nerves to reduce or remove afferent neural signals from the peripheral chemoreceptor.

Endovascular catheters and methods for carotid body ablation

Growing community of inventors

Salt Lake City, UT, United States of America

Zoar Jacob Engelman